Marker Therapeutics, Inc. Net Income Loss

• Marker Therapeutics, Inc. showed a decrease of -13.3% in Net Income Loss from 2024 to 2025.
• This data is from Marker Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
• XBRL data for this metric is available from 2000 to 2025 (26 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 26 years of available data (2000 to 2025), Marker Therapeutics, Inc.'s Net Income Loss has declined by 1,200.5%.
• Historical annual values: Fiscal year 2025: -$12.16 million | Fiscal year 2024: -$10.73 million | Fiscal year 2023: -$8.24 million | Fiscal year 2022: -$29.93 million | Fiscal year 2021: -$41.88 million | Fiscal year 2020: -$28.71 million | Fiscal year 2019: -$21.43 million | Fiscal year 2018: -$147.96 million | Fiscal year 2017: -$10.98 million | Fiscal year 2016: -$2.46 million | Fiscal year 2015: -$34.07 million | Fiscal year 2014: -$30.88 million | Fiscal year 2013: -$5.53 million | Fiscal year 2012: -$5.86 million | Fiscal year 2011: -$2.03 million | Fiscal year 2010: -$3.53 million | Fiscal year 2009: -$17.35 million | Fiscal year 2008: -$2.20 million | Fiscal year 2007: -$3.89 million | Fiscal year 2006: -$1.30 million | Fiscal year 2005: -$985.6 thousand | Fiscal year 2004: -$2.68 million | Fiscal year 2003: -$5.78 million | Fiscal year 2002: -$2.28 million | Fiscal year 2001: -$672.0 thousand | Fiscal year 2000: -$935.3 thousand.
• Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: June 21, 2026